Crossmark

BORN study: a multicenter randomized trial investigating cord blood red blood cell transfusions to reduce the severity of retinopathy of prematurity in extremely low gestational age neonates

Crossref DOI link: https://doi.org/10.1186/s13063-022-06949-8

Published Online: 2022-12-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teofili, Luciana http://orcid.org/0000-0002-7214-1561
Papacci, Patrizia

Orlando, Nicoletta

Bianchi, Maria

Pasciuto, Tina

Mozzetta, Iolanda

Palluzzi, Fernando

Giacò, Luciano

Giannantonio, Carmen

Remaschi, Giulia

Santosuosso, Michela

Beccastrini, Enrico

Fabbri, Marco

Valentini, Caterina Giovanna

Bonfini, Tiziana

Cloclite, Eleonora

Accorsi, Patrizia

Dragonetti, Antonella

Cresi, Francesco

Ansaldi, Giulia

Raffaeli, Genny

Villa, Stefania

Pucci, Giulia

Mondello, Isabella

Santodirocco, Michele

Ghirardello, Stefano

Vento, Giovanni
Funding

Funding for this research was provided by:

Fresenius HemoCare
License Information

Text and Data Mining valid from 2022-12-13

Version of Record valid from 2022-12-13
More Information

Article History

Received: 11 September 2022

Accepted: 22 November 2022

First Online: 13 December 2022

Declarations

:

: BORN has been approved by the Ethics Committee of Fondazione Policlinico A. Gemelli IRCCS, and from Ethics Committees of all participating centers. Written, informed consent to participate in the study will be obtained from parents or legal guardians of enrolled neonates.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below